LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

Search

United Therapeutics Corp

Закрыт

СекторЗдравоохранение

532.11 13.11

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

471.31

Макс.

534.67

Ключевые показатели

By Trading Economics

Доход

29M

339M

Продажи

900K

800M

P/E

Средняя по отрасли

17.995

108.767

Рентабельность продаж

42.364

Сотрудники

1,305

EBITDA

26M

463M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+17.27% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

25 февр. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

2.7B

21B

Предыдущая цена открытия

519

Предыдущая цена закрытия

532.11

Новостные настроения

By Acuity

17%

83%

23 / 351 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Weak Bullish Evidence

United Therapeutics Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 февр. 2026 г., 23:07 UTC

Отчет

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 февр. 2026 г., 23:01 UTC

Отчет

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 февр. 2026 г., 22:59 UTC

Отчет

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24 февр. 2026 г., 22:42 UTC

Отчет

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24 февр. 2026 г., 22:24 UTC

Приобретения, слияния, поглощения

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24 февр. 2026 г., 23:46 UTC

Обсуждения рынка

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24 февр. 2026 г., 23:36 UTC

Обсуждения рынка

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24 февр. 2026 г., 23:30 UTC

Обсуждения рынка

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24 февр. 2026 г., 23:20 UTC

Обсуждения рынка

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24 февр. 2026 г., 23:20 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

24 февр. 2026 г., 23:16 UTC

Отчет

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24 февр. 2026 г., 23:13 UTC

Отчет

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24 февр. 2026 г., 23:12 UTC

Отчет

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24 февр. 2026 г., 23:10 UTC

Отчет

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24 февр. 2026 г., 23:10 UTC

Отчет

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24 февр. 2026 г., 23:08 UTC

Отчет

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24 февр. 2026 г., 23:07 UTC

Отчет

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24 февр. 2026 г., 22:52 UTC

Отчет

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 февр. 2026 г., 22:46 UTC

Отчет

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 февр. 2026 г., 22:31 UTC

Приобретения, слияния, поглощения

Warner Receives New Bid From Paramount -- 3rd Update

24 февр. 2026 г., 22:29 UTC

Отчет

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24 февр. 2026 г., 22:28 UTC

Отчет

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24 февр. 2026 г., 22:27 UTC

Отчет

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24 февр. 2026 г., 22:27 UTC

Отчет

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24 февр. 2026 г., 22:25 UTC

Отчет

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24 февр. 2026 г., 22:24 UTC

Отчет

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24 февр. 2026 г., 22:23 UTC

Отчет

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24 февр. 2026 г., 22:22 UTC

Отчет

Woolworths Interim Dividend 45 Australian Cents/Share

24 февр. 2026 г., 22:22 UTC

Отчет

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24 февр. 2026 г., 22:21 UTC

Отчет

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Сравнение c конкурентами

Изменение цены

United Therapeutics Corp Прогноз

Целевая цена

By TipRanks

17.27% рост

Прогноз на 12 месяцев

Средняя 555.2 USD  17.27%

Максимум 645 USD

Минимум 423 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для United Therapeutics Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

6 ratings

4

Покупка

2

Удержание

0

Продажа

Техническая оценка

By Trading Central

292.345 / 309.245Поддержка и Сопротивление

Краткосрочная

Weak Bullish Evidence

Среднесрочная

Weak Bullish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

23 / 351Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
help-icon Live chat